{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:13:19Z","timestamp":1768997599549,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose\/Background<\/jats:title>\n                    <jats:p>The specific identification of residual\/recurrent juvenile nasal angiofibroma (JNA) following surgical treatment remains difficult. Contrast MRI and CT may not enable the differentiation of tumor from postsurgical reparative tissue. Functional imaging with prostate-specific membrane antigen (PSMA) PET\/CT targeting tumor-associated neovasculature has recently demonstrated universal positive uptake in primary JNA and offers promise of greater accuracy in the detection or exclusion of recurrent\/residual JNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective study, 18 postsurgical JNA patients with high suspicion for residual disease evinced by follow-up MR scan, or nasal endoscopy, or recent epistaxis during September 2018\u2013November 2019 were included. All patients underwent head and neck spot PSMA PET\/CT imaging. Postcontrast enhancement of a definite lesion was considered as a criterion for residual\/recurrent tumor in contrast-enhanced MRI (CEMRI). In PSMA PET\/CT, any abnormal uptake apart from physiological sites in the head and neck was considered as residual lesions. Radiological results were categorized as negative, suspicious, and residual\/recurrent tumors. Any discrepancy between CEMRI and PSMA was resolved by surgical biopsies. The sensitivity, specificity, and positive and negative predictive values were separately calculated for CEMRI and PSMA PET\/CT for diagnosing residual lesions. The interrater agreement \u03ba value was also calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On CEMRI evaluation, 14 of 18 patients had residual tumors, 2 had suspicious residual lesions, and 2 had normal postoperative scans. On PSMA PET\/CT, 12 of 18 patients had residual tumors, and 6 had normal negative scans. Surgical biopsy in all 4 discordant cases was negative for tumors and revealed only fibrosis. In 1 patient with residual tumor on both scans, discrepancy was noted with regard to tumor extent demonstrated by the 2 scans, and further surgical excision confirmed the imaging findings of PSMA PET\/CT as accurate. The sensitivity, specificity, and positive and negative predictive values of CEMRI were 100%, 33.33%, and 75% and 100%, respectively. The sensitivity, specificity, and positive and negative predictive values of PSMA PET\/CT were 100% for all parameters. The interrater agreement between the 2 tests (\u03ba) is 0.5 (95% confidence interval, 0.19\u20130.81).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT is noted as more specific than the current standard of CEMRI in the identification of residual\/recurrent JNA. It is the first radionuclide imaging scan that has found application in postoperative assessment of JNA.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration:<\/jats:bold>\n                      Clinical Trials Registry of India (CTRI\/2018\/08\/015479).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003311","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T15:08:21Z","timestamp":1602860901000},"page":"e498-e504","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Prostate-Specific Membrane Antigen PET\/CT and Contrast-Enhanced Magnetic Resonance Imaging in Follow-up Assessment of Juvenile Nasal Angiofibroma\u2014A Novel Pilot Study"],"prefix":"10.1097","volume":"45","author":[{"given":"Alok","family":"Thakar","sequence":"first","affiliation":[{"name":"Otorhinolaryngology & Head and Neck Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirabu","family":"Sakthivel","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology & Head and Neck Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreedharan Thankarajan","family":"Arunraj","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashu Seith","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aanchal","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Pathology, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology & Head and Neck Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"bib1-20260120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/hed.24696","article-title":"Nasal juvenile angiofibroma: current perspectives with emphasis on management","volume":"39","year":"2017","journal-title":"Head Neck"},{"key":"bib2-20260120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1288\/00005537-198802000-00010","article-title":"Juvenile nasopharyngeal angiofibroma: an update of the UCLA experience, 1960\u20131985","volume":"98","year":"1988","journal-title":"Laryngoscope"},{"key":"bib3-20260120","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s003300050468","article-title":"Postoperative follow-up of juvenile nasopharyngeal angiofibromas: assessment by CT scan and MR imaging","volume":"8","year":"1998","journal-title":"Eur Radiol"},{"key":"bib4-20260120","first-page":"412545","article-title":"Juvenile angiofibroma: evolution of management","volume":"2012","year":"2012","journal-title":"Int J Pediatr"},{"key":"bib5-20260120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by radioligands in non-prostate disease\u2014current status and future perspectives","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20260120","first-page":"3192","article-title":"Five different anti\u2013prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","year":"1999","journal-title":"Cancer Res"},{"key":"bib7-20260120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib8-20260120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/RLU.0000000000002928","article-title":"Prostate-specific membrane antigen expression in primary juvenile nasal angiofibroma\u2014a pilot study","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib9-20260120","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/RLU.0000000000002387","article-title":"Juvenile nasal angiofibroma on 68Ga-PSMA PET\/CT: opening new frontiers","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib10-20260120","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1097\/RLU.0000000000002745","article-title":"Clinical utility of 68Ga\u2013prostate-specific membrane antigen PET\/CT scan on postoperative assessment of juvenile nasal angiofibroma","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib11-20260120","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/RLU.0000000000002951","article-title":"Comparison of 68Ga-PSMA PET\/CT and contrast-enhanced MRI on residual disease assessment of juvenile nasal angiofibroma","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib12-20260120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2273.1986.tb01926.x","article-title":"Juvenile angiofibroma: imaging by magnetic resonance, CT and conventional techniques","volume":"11","year":"1986","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"bib13-20260120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/019459989210600315","article-title":"Treatment of large juvenile nasopharyngeal angiofibroma","volume":"106","year":"1992","journal-title":"Otolaryngol Head Neck Surg"},{"key":"bib14-20260120","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/modpathol.2012.66","article-title":"High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity","volume":"25","year":"2012","journal-title":"Mod Pathol"},{"key":"bib15-20260120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00259-016-3563-6","article-title":"68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20260120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10456-016-9521-x","article-title":"Prostate-specific membrane antigen (PSMA)\u2013mediated laminin proteolysis generates a pro-angiogenic peptide","volume":"19","year":"2016","journal-title":"Angiogenesis"},{"key":"bib17-20260120","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1097\/RLU.0000000000003041","article-title":"Fusion 68Ga\u2013prostate-specific membrane antigen PET\/MRI on postoperative surveillance of juvenile nasal angiofibroma [published online May 11, 2020]","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib18-20260120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13139-019-00628-4","article-title":"Clinical applications of 68Ga-PSMA PET\/CT on residual disease assessment of juvenile nasopharyngeal angiofibroma (JNA)","volume":"54","year":"2020","journal-title":"Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:00:36Z","timestamp":1768946436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003311","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}